The GLP-1 Agonist Paradox in Parkinson’s Disease: A Comparative Analysis of Lixisenatide and Exenatide Phase III Trial Outcomes and Neuroprotective Mechanisms
Objective: To assess the pharmacological and methodological factors underlying the "GLP-1 paradox" by comparing the outcomes of lixisenatide and exenatide, with an emphasis on kinetics,…PPAR-γ-dependent Neuroprotection by Ferulic acid improves Motor deficits in 3-nitropropionic acid model of Huntington’s disease in rats
Objective: This study investigates the neuroprotective role of FA in 3-nitropropionic acid (3-NP) model of HD through PPAR-γ–mediated mechanisms. Background: Huntington disease (HD) is a…Irisin as a Molecular Mediator of Exercise Induced Neuroprotection and Disease Modification in Parkinson’s Disease
Objective: To integrate mechanistic evidence delineating irisin mediated molecular pathways relevant to Parkinson’s disease (PD) pathogenesis and neuroprotection, focusing on α-syn clearance, autophagy–lysosomal function, mitochondrial…Pharmacogenomic Analysis of KM-819-Related Hepatotoxicity in Patients with Multiple System Atrophy
Objective: This study aimed to identify genetic risk factors linked to a drug candidate for MSA (KM-819)-associated drug-induced liver injury (DILI) in patients with multiple…Systemic antioxidant response to bilateral anodal transcranial direct current stimulation in Parkinson’s disease: findings from a pilot randomized controlled study
Objective: To investigate whether repeated sessions of bilateral anodal tDCS can influence circulating antioxidant enzyme levels and fatigue severity in individuals with Parkinson’s disease. Background:…GLP-1 Receptor Agonists in Movement Disorders: From Parkinson’s Disease to the Broader Spectrum — Mechanisms, Evidence, and Future Directions
Objective: To provide a comprehensive narrative review of the mechanistic rationale and clinical evidence for GLP-1 RA use across the spectrum of movement disorders, including…A Phase 1b Study to Investigate Safety, Tolerability and Biomarker Responses of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease
Objective: The aim of this study was to investigate safety, tolerability and biomarker responses of repeated subcutaneous (s.c.) doses of HER-096 in subjects with Parkinson’s…Baicalein Attenuates Rotenone-Induced Neurodegeneration by Regulating BDNF/CREB/Akt Signaling in Parkinson’s Disease
Objective: To evaluate the therapeutic potential of baicalein and to investigate its underlying neuroprotective mechanism in a rotenone-induced mouse model of Parkinson’s disease. Background: Parkinson’s…Intranasal Delivery of Berberine-Loaded Solid Lipid Nanoparticles Ameliorates Neuropathological and Behavioral Deficits in a Preclinical Alzheimer’s Model
Objective: To evaluate the pharmacokinetic profile and neuroprotective efficacy of intranasally administered berberine-loaded solid lipid nanoparticles (BE-SLN) in a streptozotocin (STZ)-induced rat model of Alzheimer’s…GCase and Ganglioside GM1 Interaction in Parkinson’s Disease
Objective: The project aims to further understand the role of the ganglioside GM1 in the relationship between GBA1 mutations and higher α-synuclein levels. Background: Among…
- 1
- 2
- 3
- …
- 15
- Next Page »